ジェネリック注射剤の世界市場は、2021年には1,340億米ドルとなり、北アメリカ地域が地域別市場シェアをリードしています。ジェネリック注射剤市場の成長を促す主な要因としては、ブランド薬の特許切れ、ジェネリック医薬品認可の増加、高齢者人口の増加、世界人口における生命を脅かす疾患の有病率の増加などが挙げられます。さらに、ブランド薬のコストと比較して、ジェネリック注射剤は比較的安価であり、癌、心血管疾患、糖尿病などの主要な疾患の治療に使用され、市場の需要をさらに後押ししています。
アジア太平洋地域は、インド企業の複合型ジェネリック医薬品への注力や、コスト効率の良さからジェネリック注射剤の採用が進んでいることから、最も成長率の高い地域と推定されます。また、アジア太平洋地域（中国、インド）では、さまざまな慢性疾患の有病率が最も高く、今後数年間で市場の成長に拍車がかかると予測されています。一方、世界のジェネリック注射剤市場は、北アメリカが引き続き支配的な地域であると考えられます。北アメリカ地域の米国とアジア太平洋地域の中国が、世界のジェネリック注射剤市場における主要国となっています。
COVID-19（新型コロナウイルス感染症）の発生は、病院、医療サービス、医薬品メーカーに大きな影響を与え、社会的距離、旅行制限、国境閉鎖、集会制限、在宅勤務など、世界各国の政府による様々な制限を受けたため、世界のジェネリック注射剤市場に影響を及ぼしました。COVID-19は、需要と供給の両方に直接的な影響を与え、多くの注射剤が時間通りに市場に届かないなど、サプライチェーンに混乱が生じました。製薬業界におけるCOVID-19の影響は、他の業界と比べるとやや小さいものの、それでもいくつかの点で被害を受けています。パンデミックにより、研究者が研究所を訪れることができず、進行中の臨床試験を継続することができなかったため、多くの臨床試験が遅れています。もし混乱がなければ、これらの分子は特許を取得した分子として市場に出てくるので、予測期間中にジェネリック注射剤市場が拡大することになります。
ファイザー（Pfizer Inc.）社は、世界有数のジェネリック注射剤メーカーであり、複数のジェネリック注射剤の導入や地域製薬会社との合併・提携により、その地位を強化しています。最近では2021年にファイザー社がアメリカの製薬会社イーライリリー（Eli Lilly and Company）社と提携し、変形性関節症の痛みを治療するジェネリック注射剤「タネツマブ（tanezumab）」のアメリカでの承認を発表しています。今後、さらに多くのブランド薬の特許が切れるため、ファイザー社はこれらの注射剤のジェネリック版を開発し、FDAの承認を得て市場に投入するという明確な計画を持っています。
目次
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Generic Injectables Market: Product Overview
4. Global Generic Injectables Market: An Analysis
4.1 Market Size, By Value, 2017-2027
4.2 Global Generic Injectables Market: Growth & Forecast
4.3 Impact of COVID-19 on Generic Injectables Market
5. Global Generic Injectables Market Segmentation, By Molecule Type (Value)
5.1 Competitive Scenario of Global Generic Injectables Market: By Molecule Type
5.2 Global Generic Injectables Market: Segment Analysis
5.3 By Small Molecule - Market Size and Forecast (2017-2027)
5.4 By Large Molecule - Market Size and Forecast (2017-2027)
6. Global Generic Injectables Market Segmentation, By Therapeutic Area (Value)
6.1 Competitive Scenario of Global Generic Injectables Market: By Therapeutic Area (2021 & 2027)
6.2 Global Generic Injectables Market: Segment Analysis
6.3 By Oncology - Market Size and Forecast (2017-2027)
6.4 By Anti-infectives - Market Size and Forecast (2017-2027)
6.5 By Cardiovascular - Market Size and Forecast (2017-2027)
6.6 By Diabetes - Market Size and Forecast (2017-2027)
6.7 By Others - Market Size and Forecast (2017-2027)
7. Global Generic Injectables Market Segmentation, By Container (Value)
7.1 Competitive Scenario of Global Generic Injectables Market: By Container (2021 & 2027)
7.2 Global Generic Injectables Market: Segment Analysis
7.3 By Vials - Market Size and Forecast (2017-2027)
7.4 By Ampoules - Market Size and Forecast (2017-2027)
7.5 By Pre-filled Syringes - Market Size and Forecast (2017-2027)
7.6 By Others - Market Size and Forecast (2017-2027)
8. Global Generic Injectables Market: Regional Analysis
8.1 Competitive Scenario of Global Generic Injectables Market: By Region (2021 & 2027)
9. North America Generic Injectables Market: An Analysis (2017-2027)
9.1 North America Generic Injectables Market: Size and Forecast (2017-2027), By Value
9.2 North America Generic Injectables Market - Prominent Companies
9.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
9.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
9.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
9.6 North America Generic Injectables Market: Country Analysis
9.7 Market Opportunity Chart of North America Generic Injectables Market - By Country, By Value (Year-2026)
9.8 Competitive Scenario of North America- By Country
9.9 United States Generic Injectables Market: Size and Forecast (2017-2027), By Value
9.10 United States Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
9.11 Canada Generic Injectables Market: Size and Forecast (2017-2027), By Value
9.12 Canada Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
10. Europe Generic Injectables Market: An Analysis (2017-2027)
10.1 Europe Generic Injectables Market by value: Size and Forecast (2017-2027)
10.2 Europe Generic Injectables Market: Prominent Companies
10.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
10.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
10.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
10.6 Europe Generic Injectables Market: Country Analysis
10.7 Market Opportunity Chart of Europe Generic Injectables Market - By Country, By Value (Year-2026)
10.8 Competitive Scenario of Europe Generic Injectables Marketñ By Country (2021 & 2027)
10.9 Germany Generic Injectables Market: Size and Forecast (2017-2027)
10.10 Germany Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
10.11 United Kingdom Generic Injectables Market: Size and Forecast (2017-2027)
10.12 United Kingdom Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
10.13 France Generic Injectables Market: Size and Forecast (2017-2027)
10.14 France Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
10.15 Italy Generic Injectables Market: Size and Forecast (2017-2027)
10.16 Italy Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
11. Asia Pacific Generic Injectables Market: An Analysis (2017-2027)
11.1 Asia Pacific Generic Injectables Market by value: Size and Forecast (2017-2027)
11.2 Asia Pacific Generic Injectables Market: Prominent Companies
11.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
11.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
11.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
11.6 Asia Pacific Generic Injectables Market: Country Analysis
11.7 Market Opportunity Chart of Asia Pacific Generic Injectables Market - By Country, By Value (Year-2026)
11.8 Competitive Scenario of Asia Pacific Generic Injectables Market - By Country (2021 & 2027)
11.9 China Generic Injectables Market: Size and Forecast (2017-2027)
11.10 China Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
11.11 Japan Generic Injectables Market: Size and Forecast (2017-2027)
11.12 Japan Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
11.13 India Generic Injectables Market: Size and Forecast (2017-2027)
11.14 India Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
11.15 Australia Generic Injectables Market: Size and Forecast (2017-2027)
11.16 Australia Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
12. Global Generic Injectables Market Dynamics
12.1 Global Generic Injectables Market Drivers
12.2 Global Generic Injectables Market Restraints
12.3 Global Generic Injectables Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness Chart of Global Generic Injectables Market - By Molecule Type (Year 2027)
13.2 Market Attractiveness Chart of Global Generic Injectables Market - By Therapeutic Area (Year 2027)
13.3 Market Attractiveness Chart of Global Generic Injectables Market ñ By Container (Year 2027)
13.4 Market Attractiveness Chart of Global Generic Injectables Market ñ By Region (Year 2027)
14. Competitive Landscape
14.1 Market Share of global leading companies
14.2 Market Share of Leading US Companies by Value & by Volume
14.3 SWOT Analysis - Global Generic Injectables Market
15. Global Generic Injectables Market: List of First-Time Generic Injectables Approvals in 2021
16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
16.1 Pfizer Inc.
16.2 Novartis
16.3 Sanofi
16.4 Baxter International
16.5 Fresenius SE & Co KGaA
16.6 Amneal Pharmaceuticals
16.7 Hikma Pharmaceuticals
16.8 Gland Pharma
16.9 Teva Pharmaceuticals
16.10 Nichi-iko Pharmaceutical
List of Figures
Figure 1: Global Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 2: Global Estimated number of Cancer incidences and prevalent cases (all ages, in millions), Year 2020
Figure 3: Global Cancer related number of deaths (all ages, in thousand's), Year 2020
Figure 4: Global Estimated number of Diabetes prevalent cases (adults (20-79), in millions), Year 2021
Figure 5: Global Prevalence of Cardiovascular Diseases, (in million), 2015-2019
Figure 6: Global Aged Population (Above 65), 2015-20 (% of total Population)
Figure 7: Global Aged Population (Above 65), By Country, 2020 (% of total Population)
Figure 8: Global Medical Spending in 2020, By Region, (% of Total)
Figure 9: Current Healthcare Expenditure (% Share of GDP), By Selected Country, 2016-2020 (In %)
Figure 10: Global Expected Healthcare Industry Outlook
Figure 11: Regional Expected Healthcare Industry Growth Rate By Year 2024
Figure 12: Global Generic Injectables Market- By Molecule Type Market Share, 2021 & 2027
Figure 13: Global Generic Injectables Market- By Small Molecule, By Value (USD Billion), 2017-2027
Figure 14: Global Generic Injectables Market- By Large Molecule, By Value (USD Billion), 2017-2027
Figure 15: Global Generic Injectables Market - By Therapeutic Area Market Share, 2021 & 2027
Figure 16: Global Generic Injectables Market- By Oncology, By Value (USD Billion), 2017-2027
Figure 17: Global Generic Injectables Market- By Anti-infectives, By Value (USD Billion), 2017-2027
Figure 18: Global Generic Injectables Market- By Cardiovascular, By Value (USD Billion), 2017-2027
Figure 19: Global Generic Injectables Market- By Diabetes, By Value (USD Billion), 2017-2027
Figure 20: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027
Figure 21: Global Generic Injectables Market- By Container Market Share, 2021 & 2027
Figure 22: Global Generic Injectables Market- By Vials, By Value (USD Billion), 2017-2027
Figure 23: Global Generic Injectables Market- By Ampoules, By Value (USD Billion), 2017-2027
Figure 24: Global Generic Injectables Market- By Pre-filled Syringes, By Value (USD Billion), 2017-2027
Figure 25: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027
Figure 26: Global Generic Injectables Market- By Region Market Share, 2021 & 2027
Figure 27: North America Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 28: Prevalence of Cardiovascular Diseases in North America, (in million), 2015-2019
Figure 29: Cancer prevalence in North America (in million), Year 2020
Figure 30: Prevalence of Multiple Sclerosis in North America, (in 1000ís), 2015-2019
Figure 31: North America Diabetes Prevalence, By Country, 2020 (% of Population Aged 20-79)
Figure 32: North America Diabetes-related health expenditure per person, USD (Year 2021)
Figure 33: North America Current health expenditure per capita (current USD), 2014-18
Figure 34: North America Population ages 65 and above (% of total Population), 2016-20
Figure 35: North America Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 36: North America Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 37: North America Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 38: Market Opportunity Chart of North America Generic Injectables Market- By Country, By Value (Year-2027)
Figure 39: North America Generic Injectables Market- By Country Market Share, 2021 & 2027
Figure 40: United States Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 41: Prevalence of Cardiovascular Diseases in United States, (in million), 2015-2019
Figure 42: Prevalence of Multiple Sclerosis in United States, (in 1000ís), 2016-2019
Figure 43: Cancer prevalence in United States (in million), Year 2020
Figure 44: United States Current health expenditure per capita (current USD), 2016-2020
Figure 45: United States Population aged 65 and above (% of total Population), 2016-20
Figure 46: Estimated people with diabetes in United States (in millions), 2021-2045
Figure 47: United States Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 48: United States Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 49: United States Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 50: Canada Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 51: Prevalence of Cardiovascular Diseases in Canada, (in million), 2015-2019
Figure 52: Estimated number of Cancer Prevalent cases in Canada, 2020
Figure 53: Prevalence of Multiple sclerosis in Canada, (in 1000ís), 2016-2019
Figure 54: Canada Current health expenditure per capita (current USD), 2017-2021
Figure 55: Canada Population aged 65 and above (% of total Population), 2016-20
Figure 56: Estimated people with diabetes in Canada (in millions), 2021-2045
Figure 57: Canada Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 58: Canada Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 59: Canada Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 60: Europe Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 61: Europe Prevalence of Cardiovascular Diseases (in Million), 2015-2019
Figure 62: Prevalence of Osteoarthritis Diseases in Europe, (in Million), 2015-2019
Figure 63: Europe estimated number of Cancer prevalence (all ages, in Million), Year 2020
Figure 64: Europe Prevalence of Multiple Sclerosis, 2016-2019 (In 1000ís)
Figure 65: Europe Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)
Figure 66: Europe Current health expenditure per capita (current USD), 2015-18
Figure 67: Total expenditure on health per capita in European countries (in USD PPP), 2019
Figure 68: Population ages 65 and above (% of total Population) in European Countries, 2020
Figure 69: Europe Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 70: Europe Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 71: Europe Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 72: Market Opportunity Chart of Europe Generic Injectables Market- By Country, By Value (Year-2026)
Figure 73: Europe Generic Injectables Market- By Country Market Share, 2021 & 2027
Figure 74: Germany Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 75: Prevalence of Cardiovascular Diseases in Germany, (in million), 2015-2019
Figure 76: Estimated people with diabetes in Germany (in millions), 2021-2045
Figure 77: Prevalence of Multiple Sclerosis in Germany, (in 1000ís), 2016-2019
Figure 78: Germany Current health expenditure per capita (current USD), 2015-2019
Figure 79: Germany Population aged 65 and above (% of total Population), 2016-20
Figure 80: Germany, Estimated percentage of prevalent Cancer cases, 2020
Figure 81: Germany Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 82: Germany Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 83: Germany Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 84: United Kingdom Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 85: Estimated people with diabetes in United Kingdom (in millions), 2021-2045
Figure 86: United Kingdom, Estimated percentage of prevalent Cancer cases, 2020
Figure 87: Prevalence of Multiple Sclerosis in United Kingdom, (in 1000ís), 2015-2019
Figure 88: United Kingdom Current health expenditure per capita (current USD), 2015-2019
Figure 89: United Kingdom Population aged 65 and above (% of total Population), 2016-20
Figure 90: Prevalence of Cardiovascular Diseases in United Kingdom, (in million), 2015-2019
Figure 91: United Kingdom Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 92: United Kingdom Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 93: United Kingdom Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 94: France Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 95: Estimated people with diabetes in France (in millions), 2021-2045
Figure 96: France, Estimated percentage of prevalent Cancer cases, 2020
Figure 97: Prevalence of Multiple Sclerosis in France, (in 1000ís), 2015-2019
Figure 98: France Current health expenditure per capita (current USD), 2015-2019
Figure 99: France Population aged 65 and above (% of total Population), 2016-20
Figure 100: Prevalence of Cardiovascular Diseases in France, (in million), 2015-2019
Figure 101: France Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 102: France Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 103: France Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 104: Italy Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 105: Estimated people with diabetes in Italy (in millions), 2021-2045
Figure 106: Italy, Estimated percentage of prevalent Cancer cases, 2020
Figure 107: Prevalence of Multiple Sclerosis in Italy, (in 1000ís), 2015-2019
Figure 108: Italy Current health expenditure per capita (current USD), 2015-2019
Figure 109: Italy Population aged 65 and above (% of total Population), 2016-20
Figure 110: Prevalence of Cardiovascular Diseases in Italy, (in million), 2015-2019
Figure 111: Italy Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 112: Italy Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 113: Italy Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 114: Asia Pacific Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 115: Prevalence of Cardiovascular Diseases in Asia Pacific, (in million), 2015-2019
Figure 116: Cancer prevalence in Asia Pacific (in thousands), Year 2020
Figure 117: Asia Pacific Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)
Figure 118: Asia Pacific Current health expenditure per capita (current USD), 2014-18
Figure 119: Asia Pacific, Current health expenditure per capita, by countries (current USD), 2019
Figure 120: Asia Pacific, Population ages 65 and above (% of total Population), 2016-20
Figure 121: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Figure 122: Asia Pacific Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 123: Asia Pacific Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 124: Asia Pacific Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 125: Market Opportunity Chart of Asia Pacific Generic Injectables Market- By Country, By Value (Year-2026)
Figure 126: Asia Pacific Generic Injectables Market- By Country Market Share, 2021 & 2027
Figure 127: China Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 128: Estimated people with diabetes in China (in millions), 2021-2045
Figure 129: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 130: Estimated number of Cancer prevalent cases in China (all ages, in 1000ís), Year 2020
Figure 131: China Current health expenditure per capita (current USD), 2015-2019
Figure 132: China Population aged 65 and above (% of total Population), 2016-20
Figure 133: China Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 134: China Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 135: China Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 136: Japan Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 137: Estimated people with diabetes in Japan (in millions), 2021-2045
Figure 138: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 139: Estimated number of Cancer prevalent cases in Japan (all ages, in 1000ís), Year 2020
Figure 140: Japan Healthcare Expenditure Outlook (%)
Figure 141: Japan Population aged 65 and above (% of total Population), 2016-20
Figure 142: Japan Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 143: Japan Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 144: Japan Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 145: India Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 146: Estimated people with diabetes in India (in millions), 2021-2045
Figure 147: Estimated number of Cancer prevalent cases in India (all ages, in 1000ís), Year 2020
Figure 148: Prevalence of Multiple Sclerosis in India, (in 1000ís), 2016-2019
Figure 149: Estimated value of public health spending in India (from 2017-20, in billions USD)
Figure 150: India Population aged 65 and above (% of total Population), 2016-20
Figure 151: Prevalence of Cardiovascular Diseases in India, (in million), 2015-2019
Figure 152: India Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 153: India Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 154: India Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 155: Australia Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 156: Estimated people with diabetes in Australia (in millions), 2021-2045
Figure 157: Estimated number of Cancer prevalent cases in Australia (all ages, in 1000ís), Year 2020
Figure 158: Prevalence of Multiple Sclerosis in Australia, (in 1000ís), 2016-2019
Figure 159: Australia Current health expenditure per capita (current USD), 2015-2019
Figure 160: Australia Population aged 65 and above (% of total Population), 2016-20
Figure 161: Prevalence of Cardiovascular Diseases in Australia, (in million), 2015-2019
Figure 162: Australia Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 163: Australia Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 164: Australia Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 165: Market Attractiveness Chart of Global Generic Injectables Market- By Molecule Type (Year-2027)
Figure 166: Market Attractiveness Chart of Global Generic Injectables Market- By Therapeutic Area (Year-2027)
Figure 167: Market Attractiveness Chart of Global Generic Injectables Market- By Container (Year-2027)
Figure 168: Market Attractiveness Chart of Global Generic Injectables Market- By Region (Year-2027)
Figure 169: Global Generic Injectables company market share (%), 2021
Figure 170: Market share in generic injectables in US (by value), 2021
Figure 171: Market share in generic injectables in US (by volume), 2021
Figure 172: Pfizer Inc. Annual Sales Revenue, 2016-2020 (USD Million)
Figure 173: Pfizer Inc. Net Income, 2016-2020 (USD Million)
Figure 174: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020
Figure 175: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 176: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 177: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 178: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 179: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 180: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 181: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 182: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 183: Baxter International Sales Revenues, 2016-2020 (USD Million)
Figure 184: Baxter International Net Income, 2016-2020 (USD Million)
Figure 185: Baxter International Sales Revenue Split, By Business Segment (%), FY2020
Figure 186: Baxter International Sales Revenue Split, By Geography Segment (%), FY2020
Figure 187: Fresenius SE & Co KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 188: Fresenius SE & Co KGaA Net Income, 2016-2020 (USD Million)
Figure 189: Fresenius SE & Co KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 190: Fresenius SE & Co KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 191: Amneal Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
Figure 192: Amneal Pharmaceuticals Net Income, 2016-2020 (USD Million)
Figure 193: Amneal Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
Figure 194: Amneal Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
Figure 195: Hikma Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
Figure 196: Hikma Pharmaceuticals Net Income, 20016-2020 (USD Million)
Figure 197: Hikma Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
Figure 198: Hikma Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
Figure 199: Gland Pharma Annual Sales Revenue (USD Million), 2017-2020
Figure 200: Gland Pharma Net Income (USD Million), 2017-2020
Figure 201: Gland Pharma Sales Revenue, By Business Segment (%), FY2020
Figure 202: Gland Pharma Sales Revenue, By Geographical Segment (%), FY2020
Figure 203: Teva Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
Figure 204: Teva Pharmaceuticals Net Income, 2016-2020 (USD Million)
Figure 205: Teva Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
Figure 206: Teva Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
Figure 207: Nichi-iko Pharmaceutical Sales Revenues, 2016-2020 (USD Million)
Figure 208: Nichi-iko Pharmaceutical Net Income, 2016-2020 (USD Million)
Figure 209: Nichi-iko Pharmaceutical Sales Revenue Split, By Business Segment (%), FY2020
Figure 210: Nichi-iko Pharmaceutical Sales Revenue Split, By Geography Segment (%), FY2020
